4D Molecular Therapeutics FDMT Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's accretion (amortization) of discounts and premiums, investments?
- 4D Molecular Therapeutics (FDMT) reported accretion (amortization) of discounts and premiums, investments of $1.13M in Q1 2026.
- How has 4D Molecular Therapeutics's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- 4D Molecular Therapeutics's accretion (amortization) of discounts and premiums, investments decreased by 10.5% year-over-year, from $1.27M to $1.13M.
- What is the long-term trend for 4D Molecular Therapeutics's accretion (amortization) of discounts and premiums, investments?
- Over 3 years (2021 to 2025), 4D Molecular Therapeutics's accretion (amortization) of discounts and premiums, investments has grown at a 87.4% compound annual growth rate (CAGR), from -$719K to $4.73M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- Represents the non-cash adjustment to the carrying value of investment securities to account for the amortization of premiums or the accretion of discounts over the life of the investment. This adjustment reconciles the interest income recognized in net income with the actual cash received from investment holdings. It is a standard accounting adjustment to reflect the effective interest method on debt securities.